References
Abate-Shen C, Shen MM. 2000. Molecular genetics of prostate
cancer. Genes Dev 14: 2410–2434.
Abate-Shen C, Banach-Petrosky WA, Sun X, Economides KD,
Desai N, Gregg JP, Borowsky AD, Cardiff RD, Shen MM.
2003. Nkx3.1; Pten mutant mice develop invasive prostate
adenocarcinoma and lymph node metastases. Cancer Res 63:
3886–3890.
Abate-Shen C, Shen MM, Gelmann E. 2008. Integrating differentiation and cancer: The Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis. Differentiation 76:
717–727.
Abdulkadir SA, Magee JA, Peters TJ, Kaleem Z, Naughton CK,
Humphrey PA, Milbrandt J. 2002. Conditional loss of Nkx3.1
in adult mice induces prostatic intraepithelial neoplasia. Mol
Cell Biol 22: 1495–1503.
Abreu-Martin MT, Chari A, Palladino AA, Craft NA, Sawyers
CL. 1999. Mitogen-activated protein kinase kinase kinase 1
activates androgen receptor-dependent transcription and
apoptosis in prostate cancer. Mol Cell Biol 19: 5143–5154.
Acevedo VD, Gangula RD, Freeman KW, Li R, Zhang Y, Wang F,
Ayala GE, Peterson LE, Ittmann M, Spencer DM. 2007.
Inducible FGFR-1 activation leads to irreversible prostate
adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell 12: 559–571.
Adams JM, Strasser A. 2008. Is tumor growth sustained by rare
cancer stem cells or dominant clones? Cancer Res 68: 4018–
4021.
Adam RM, Mukhopadhyay NK, Kim J, Di Vizio D, Cinar B,
Boucher K, Solomon KR, Freeman MR. 2007. Cholesterol
sensitivity of endogenous and myristoylated Akt. Cancer
Res 67: 6238–6246.

Agoulnik IU, Vaid A, Bingman WE III, Erdeme H, Frolov A,
Smith CL, Ayala G, Ittmann MM, Weigel NL. 2005. Role of
SRC-1 in the promotion of prostate cancer cell growth and
tumor progression. Cancer Res 65: 7959–7967.
Aihara M, Wheeler TM, Ohori M, Scardino PT. 1994. Heterogeneity of prostate cancer in radical prostatectomy specimens. Urology 43: 60–66.
Albadine R, Latour M, Toubaji A, Haffner M, Isaacs WB, Platz
EA, Meeker AK, Demarzo AM, Epstein JI, Netto GJ 2009.
TMPRSS2-ERG gene fusion status in minute (minimal)
prostatic adenocarcinoma. Mod Pathol 22: 1415–1422.
Albertsen PC, Hanley JA, Fine J. 2005. 20-year outcomes
following conservative management of clinically localized
prostate cancer. JAMA 293: 2095–2101.
Alimonti A, Nardella C, Chen Z, Clohessy JG, Carracedo A,
Trotman LC, Cheng K, Varmeh S, Kozma SC, Thomas G,
et al. 2010. A novel type of cellular senescence that can be
enhanced in mouse models and human tumor xenografts
to suppress prostate tumorigenesis. J Clin Invest 120:
681–693.
Al Olama AA, Kote-Jarai Z, Giles GG, Guy M, Morrison J,
Severi G, Leongamornlert DA, Tymrakiewicz M, Jhavar S,
Saunders E, et al. 2009. Multiple loci on 8q24 associated with
prostate cancer susceptibility. Nat Genet 41: 1058–1060.
Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F,
Wallace TA, Liu CG, Volinia S, Calin GA, et al. 2008.
Genomic profiling of microRNA and messenger RNA reveals
deregulated microRNA expression in prostate cancer. Cancer Res 68: 6162–6170.
American_Cancer_Society. 2009. Cancer facts & figures 2009.
American Cancer Society, Atlanta, GA.
Amundadottir LT, Sulem P, Gudmundsson J, Helgason A, Baker
A, Agnarsson BA, Sigurdsson A, Benediktsdottir KR, Cazier
